AI Model Helps Discover Targeted Antibiotic for Crohn's Disease
The Facts
- In a study published in Nature Microbiology on Friday, researchers at MIT's Computer Science and Artificial Intelligence Laboratory and McMaster University identified a new compound, enterololin, that suppresses bacteria linked to Crohn's disease flare-ups while preserving most of the microbiome.
- The antibiotic enterololin targets a specific family of bacteria called Enterobacteriaceae, including E. coli, rather than wiping out all bacteria like broad-spectrum antibiotics that can act as indiscriminate sledgehammers in treating gut inflammation.
- Using the AI model DiffDock, researchers predicted that enterololin binds to the LolCDE protein complex within 100 seconds. This process traditionally requires years of experiments and costs around $2 million, but was completed in six months for $60,000.
Sources Split
LEFT
CENTER
RIGHT
+1
+4
ESTAB
CRIT
CENTER
PRO
ESTAB
The Spin
Techno-optimist narrative
AI and machine learning are among the most powerful tools in combating antimicrobial resistance (AMR), with revolutionary capabilities to process vast biomedical datasets and predict pathogen resistance patterns. These advanced technologies achieve remarkable accuracy rates of 95-98% in predicting resistance, dramatically reduce diagnostic time to just 3 hours, and have already enabled the discovery of 22 preclinical drug candidates since 2019.
Techno-skeptic narrative
AI drug discovery faces fundamental data quality problems that undermine its transformative potential, with inconsistent experimental methods creating batch effects that algorithms incorrectly interpret as meaningful patterns. The bias toward publishing only positive results deprives AI models of crucial failure data, while pharmaceutical companies hoard their most valuable datasets instead of sharing them for genuine scientific progress.
Metaculus Prediction
The Controversies
Go Deeper
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.17.1